Micafungine Accord

Micafungin Sodium, the active ingredient in Micafungine Accord, is an echinocandin antifungal presented as an injectable solution for intravenous use. It is employed to treat invasive candidiasis, esophageal candidiasis, and to prevent Candida infections in patients undergoing hematopoietic stem cell transplantation.

GNH USA supplies Micafungine Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and oncology clinics worldwide, adhering to EU quality standards and providing cold‑chain logistics for this parenteral product.

Micafungine Accord is used to manage fungal infections caused by Candida species, targeting invasive disease and mucosal involvement. - Invasive candidiasis: effective in clearing bloodstream, intra‑abdominal infections and peritonitis caused by Candida spp. - Esophageal candidiasis: resolves mucosal lesions and associated pain in immunocompromised patients. - Prophylaxis in hematopoietic stem cell transplantation: prevents Candida infection during the neutropenic phase of transplant conditioning.

Micafungine Accord may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Fever: transient elevation of body temperature. - Nausea: mild to moderate gastrointestinal upset. - Headache: occasional mild headache. - Elevated liver enzymes: mild increase in ALT/AST.

Serious or Rare Side Effects: - Hepatotoxicity: significant liver injury with jaundice. - Severe hypersensitivity: anaphylaxis, rash, or angioedema. - Infusion‑related reactions: hypotension, dyspnea, or chest discomfort. - Renal impairment: acute kidney injury in rare cases.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications. - Renal function: assess baseline creatinine and monitor during therapy. - Hepatic function: evaluate liver enzymes before initiation and periodically. - Concomitant azoles: avoid co‑administration with strong CYP3A4 inhibitors. - Pregnancy: use only if potential benefit justifies risk, as safety data are limited. - Pediatric use: safety and efficacy not established in children under 1 month. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungine Accord can interact with other medicines that affect its metabolism or increase toxicity risk.

Major Interactions (Avoid): - Cytochrome P450 3A4 inducers (e.g., rifampin, carbamazepine): may reduce micafungin exposure. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase micafungin levels.

Moderate Interactions (Monitor Closely): - Immunosuppressants (e.g., tacrolimus, cyclosporine): monitor drug levels as micafungin may affect metabolism. - Statins (e.g., simvastatin): observe for increased risk of myopathy. - Anticoagulants (e.g., warfarin): watch for altered INR values.